An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2008 by Korea Otsuka Pharmaceutical Co.,Ltd..
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Korea Otsuka Pharmaceutical Co.,Ltd.
ClinicalTrials.gov Identifier:
NCT00657176
First received: April 9, 2008
Last updated: April 17, 2008
Last verified: April 2008
  Purpose

This is an open-label, non-randomized, single-center, dose-escalation study in patients with advanced solid tumors. Six dose levels (100, 200, 400, 600, 800, and 1000 mg/day) are planned for the study. In this study, OPB-31121's potential for toxic effects will be evaluated in patients with advanced solid tumors to evaluate the recommended dose for use in subsequent studies. The pharmacokinetics and antitumor effect of the compound will also be investigated.


Condition Intervention Phase
Solid Tumor
Drug: OPB-31121
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Non-Randomized Study of OPB-31121 in Patients With Advanced Solid Tumors

Resource links provided by NLM:


Further study details as provided by Korea Otsuka Pharmaceutical Co.,Ltd.:

Primary Outcome Measures:
  • Maximum tolerated dose [ Time Frame: Cycle 1 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Safety and dose-limiting toxicity [ Time Frame: Duration of Study ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics [ Time Frame: Cycle 1 ] [ Designated as safety issue: No ]
  • Antitumor effect [ Time Frame: Duration of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 36
Study Start Date: March 2008
Estimated Study Completion Date: June 2009
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: OPB-31121
    • 100mg tablet
    • oral administration, Qd
  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Histologically confirmed solid tumor refractory to standard therapy or for which there is no standard therapy
  2. Age: more than 19 years
  3. ECOG performance status: less than 2
  4. Life expectancy of longer than 3 months
  5. Adequate vital organ function as follows:

    • Bone marrow function

      • neutrophils: more than 1,500 per microliter
      • platelets: more than 75,000 per microliter
      • hemoglobin: more than 10.0g per deciliter
    • Hepatic function

      • AST and ALT: less than 2.5 x institutional upper limit normal
      • serum total bilirubin: less than 2.5 x institutional ULN
    • Renal function

      • Serum creatinine: less than 1.5 x institutional ULN
  6. Capable of swallowing OPB-31121 tablets
  7. Ability to understand and willingness to sign written informed consent document for participation in the trial and for analysis of genotypes CYP2C9 and NAT2
  8. No chemotherapy, radiotherapy, surgery, or immunotherapy within 4 weeks prior to study entry and recovered from any prior toxicity

Exclusion criteria:

  1. Symptomatic CNS metastasis
  2. Uncontrolled concurrent illness, including active infection, heart failure, angina pectoris, and cardiac arrhythmia
  3. Psychiatric illness that would limit compliance with study requirements
  4. Pregnant or breast-feeding women and women of childbearing potential who cannot or will not use effective contraceptive measures
  5. Administration of another investigational agent within 6 months prior to study entry
  6. Use of CYP3A4 and CYP2C9 inducers, inhibitors, or substrates, and CYP2B6, CYP2C8 and CYP2D6 substrates
  7. Hyperlipidemia:

    Total cholesterol:more than 300 milligram per deciliter or Triglycerides:

    more than 2.5 x institutional ULN

  8. Abnormal thyroid function: Hypothyroidism or hyperthyroidism of grade 2 or higher (graded according to the NCI-CTCAE)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00657176

Contacts
Contact: Yung-Jue Bang, PhD 82-2-2072-2390 bangyj@snu.ac.kr
Contact: Hanna Lee, Bachelor 82-2-2072-0603 life1025@naver.com

Locations
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Hanna Lee, Bachelor    +82-2-2072-0603    life1025@naver.com   
Principal Investigator: Yung-Jue Bang, PhD         
Sponsors and Collaborators
Korea Otsuka Pharmaceutical Co.,Ltd.
Investigators
Principal Investigator: Yung-Jue Bang, PhD Division of Hematology and Medical Oncology, Seoul National University Hospital
  More Information

No publications provided

Responsible Party: Sol Han / Clinical Research Associate, Clinical Research Team
ClinicalTrials.gov Identifier: NCT00657176     History of Changes
Other Study ID Numbers: 252-KOA-0701
Study First Received: April 9, 2008
Last Updated: April 17, 2008
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on July 20, 2014